BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38480032)

  • 1. Stratification of Patients with Renal Cell Carcinoma by the Abundance of Sarcomatoid Features Reveals Differences in Survival and the Underlying Pathobiology.
    Salgia NJ; Aubrecht WM; Wang L; Ram B; Wasik BJ; Khan A; Attwood K; Daza J; Long MD; Eng KH; Xu B; Muhitch JB; Kauffman EC
    Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38480032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
    Adashek JJ; Zhang Y; Skelton WP; Bilotta A; Chahoud J; Zemp L; Li J; Dhillon J; Manley B; Spiess PE
    Front Oncol; 2020; 10():627025. PubMed ID: 33643921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
    Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
    Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kyriakopoulos CE; Chittoria N; Choueiri TK; Kroeger N; Lee JL; Srinivas S; Knox JJ; Bjarnason GA; Ernst SD; Wood LA; Vaishampayan UN; Agarwal N; Pal SK; Kanesvaran R; Rha SY; Yuasa T; Donskov F; North SA; Heng DY; Rini BI
    Clin Genitourin Cancer; 2015 Apr; 13(2):e79-85. PubMed ID: 25450036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.
    Shuch B; Bratslavsky G; Shih J; Vourganti S; Finley D; Castor B; Treat E; Linehan WM; Pantuck AJ; Said JW; Belldegrun AS
    BJU Int; 2012 Jun; 109(11):1600-6. PubMed ID: 22221668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.
    Blum KA; Silagy AW; Knezevic A; Weng S; Wang A; Mano R; Marcon J; DiNatale RG; Sanchez A; Tickoo S; Gupta S; Motzer R; Haas NB; Kim SE; Uzzo RG; Coleman JA; Hakimi AA; Russo P
    BJU Int; 2024 Feb; 133(2):169-178. PubMed ID: 37589200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically.
    Nguyen DP; Vilaseca A; Vertosick EA; Corradi RB; Touijer KA; Benfante NE; Sjoberg DD; Russo P
    World J Urol; 2016 Apr; 34(4):539-44. PubMed ID: 26215750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics and prognostic factors of sarcomatoid renal cell carcinoma.
    Yan Y; Liu L; Zhou J; Li L; Li Y; Chen M; Wang L; He W; Guan X; Zu X; Qi L
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):345-52. PubMed ID: 25178995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.
    Adibi M; Thomas AZ; Borregales LD; Merrill MM; Slack RS; Chen HC; Sircar K; Murugan P; Tamboli P; Jonasch E; Tannir NM; Matin SF; Wood CG; Karam JA
    Urol Oncol; 2015 Oct; 33(10):427.e17-23. PubMed ID: 26004164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
    Merrill MM; Wood CG; Tannir NM; Slack RS; Babaian KN; Jonasch E; Pagliaro LC; Compton Z; Tamboli P; Sircar K; Pisters LL; Matin SF; Karam JA
    Urol Oncol; 2015 Apr; 33(4):166.e21-9. PubMed ID: 25700975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data.
    Janisch F; Kienapfel C; Fühner C; Klotzbücher T; Marks P; Hillemacher T; Meyer CP; Iwata T; Parizi MK; Sauter G; Fisch M; Shariat SF; Dahlem R; Rink M
    Front Surg; 2021; 8():763271. PubMed ID: 34869564
    [No Abstract]   [Full Text] [Related]  

  • 14. The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis.
    Al-Juhaishi T; Deng X; Bandyopadhyay D; Paul A
    Cureus; 2022 May; 14(5):e25395. PubMed ID: 35774668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
    Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
    Rini BI; Motzer RJ; Powles T; McDermott DF; Escudier B; Donskov F; Hawkins R; Bracarda S; Bedke J; De Giorgi U; Porta C; Ravaud A; Parnis F; Grande E; Zhang W; Huseni M; Carroll S; Sufan R; Schiff C; Atkins MB
    Eur Urol; 2021 May; 79(5):659-662. PubMed ID: 32654802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma.
    Trudeau V; Larcher A; Sun M; Boehm K; Dell'Oglio P; Sosa J; Tian Z; Fossati N; Briganti A; Shariat SF; Karakiewicz PI
    World J Urol; 2016 Oct; 34(10):1429-36. PubMed ID: 26902877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
    Mano R; Flynn J; Blum KA; Silagy AW; DiNatale RG; Marcon J; Wang A; Sanchez A; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Urol Oncol; 2019 Dec; 37(12):916-923. PubMed ID: 31590969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging (MRI) helps differentiate renal cell carcinoma with sarcomatoid differentiation from renal cell carcinoma without sarcomatoid differentiation.
    Takeuchi M; Froemming AT; Kawashima A; Thapa P; Carter RE; Cheville JC; Thompson RH; Takahashi N
    Abdom Radiol (NY); 2022 Jun; 47(6):2168-2177. PubMed ID: 35381868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma.
    Kim T; Zargar-Shoshtari K; Dhillon J; Lin HY; Yue B; Fishman M; Sverrisson EF; Spiess PE; Gupta S; Poch MA; Sexton WJ
    Clin Genitourin Cancer; 2015 Jun; 13(3):225-30. PubMed ID: 25544725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.